Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy

Circulation Journal

Volumn 70, Issue 8, 2006, Pages 991-994

  Kajimoto, Hidemi ^a   Ishigaki, Keiko ^a   Okumura, Kenichi ^a   Tomimatsu, Hirofumi ^a   Nakazawa, Makoto ^a   Saito, Kayoko ^a   Osawa, Makiko ^a   Nakanishi, Toshio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitors; Carvedilol; Duchenne muscular dystrophy; Heart failure; Left ventricular function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; FOLLOW UP; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; HUMAN; MUSCULAR DYSTROPHY; SCHOOL CHILD;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBAZOLES; CARDIAC OUTPUT, LOW; CHILD; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HUMANS; MUSCULAR DYSTROPHIES; PROPANOLAMINES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33746709342     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.991     Document Type: Article

References (29)

1. Ishihara T. Management of patients with Duchenne muscular dystrophy. Nou To Hattatsu 2004; 36: 130-135.
2. Foody JM, Farrel MH, Krumholz HM. Beta-blocker therapy in heart failure. JAMA 2002; 287: 883-889.
3. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
4. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569.
5. Hara Y, Hamada M, Shigematsu Y, Suzuki M, Kodama K, Kuwahara T, et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 2000; 64: 365-369.
6. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367.
7. Mori Y, Nakazawa M, Tomimatsu H, Momma K. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: A controlled pilot study. J Am Coll Cardiol 2000; 36: 270-275.
8. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromusc Dis 2002; 12: 926-929.
9. Grenier MA, Fioravanti J, Truesdell SC, Mendelsohn AM, Vermilion RP, Lipshultz SE. Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents. Prog Pediatr Cardiol 2000; 12: 91-111.
10. Shaddy RE, Tani LY, Gidding SS, Pahl E, Orsmond GS, Gilbert EM, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: A multi-institutional experience. J Heart Lung Transplant 1999; 18: 269-274.
11. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor-blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
12. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000; 36: 1612-1618.
13. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
14. Hirooka K, Yasumura Y, Ishida Y, Hanatani A, Nakatani S, Komamura K, et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J 2001; 65: 931-936.
15. Mori T, Hayashi T, Sohmiya K, Otsuka N, Shimomura H, Ohkita M, et al. Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. Circ J 2005; 69: 596-602.
16. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999; 137: 895-902.
17. Jefferies JL, Eidem BW, Belmont JW, Gcraigen WJ, Ware SM, Fernbach SD, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112: 2799-2804.
18. Staesen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
19. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin-II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
20. Ruiz-Cano MJ, Delgado JF, Jimenez S, Cea-Calvo L, Sanchez V, Escribano P, et al. Successful heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy. Tranplant Proc 2003; 35: 1513-1515.
21. Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y, Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 2002; 23: 160-166.
22. Lanza GA, Russo AD, Giglio V, Luca LD, Messano L, Santini C, et al. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: Relationship to myocardial and respiratory function. Am Heart J 2001; 141: 808-812.
23. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J 1996; 132: 642-647.
24. Giglio V, Pasceri V, Messano L, Mangiola F, Pasquini L, Russo AD, et al. Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. J Am Coll Cardiol 2003; 43: 309-319.
25. Doing AH, Renlund DG, Smith RA. Becker muscular dystrophy-related cardiomyopathy: A favorable response to medical therapy. J Heart Lung Transplant 2002; 21: 496-498.
26. Bosser G, Lucron H, Lethor JP, Burger G, Beltramo F, Marie PY, et al. Evidence of early impairments in both right and left ventricular inotropic reserves in children with Duchenne's muscular dystrophy. Am J Cardiol 2004; 93: 724-727.
27. Ramaciotti C, Iannaccone ST, Scott WA. Myocardial cell damage in Duchenne muscular dystrophy. Pediatr Cardiol 2003; 24: 503-506.
28. Nakanishi T, Sakauchi M, Kaneda Y, Tomimatsu H, Saito K, Nakazawa K, et al. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics 2006 (in press).
29. Demachi J, Kagaya Y, Watanabe J, Sakura M, Ikeda J, Kakuta Y, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromusc Dis 2004; 14: 732-739.